IFNG and neoplasm: We then tested the CTL responses of cured mice that had remained tumor free upon re-challenge by ex-vivo IFN-γ ELISpot assays and included an E6-derived CTL epitope in addition to the E7-specific epitope in order to test for possible epitope spreading [35, 36].